Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 21 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.35 Insider Own45.96% Shs Outstand35.25M Perf Week-15.47%
Market Cap23.41M Forward P/E- EPS next Y-0.50 Insider Trans0.00% Shs Float19.05M Perf Month-56.03%
Income-12.13M PEG- EPS next Q-0.15 Inst Own5.86% Short Float1.05% Perf Quarter-76.03%
Sales37.89M P/S0.62 EPS this Y73.68% Inst Trans2.51% Short Ratio0.57 Perf Half Y-6.48%
Book/sh0.60 P/B1.11 EPS next Y-402.50% ROA-21.02% Short Interest0.20M Perf Year-14.82%
Cash/sh0.92 P/C0.73 EPS next 5Y- ROE-48.17% 52W Range0.45 - 3.25 Perf YTD-8.16%
Dividend Est.- P/FCF- EPS past 5Y18.79% ROI-56.71% 52W High-79.57% Beta1.80
Dividend TTM- Quick Ratio1.91 Sales past 5Y25.79% Gross Margin99.66% 52W Low47.56% ATR (14)0.11
Dividend Ex-DateJun 12, 2009 Current Ratio1.91 EPS Y/Y TTM58.78% Oper. Margin-34.85% RSI (14)25.29 Volatility8.86% 10.87%
Employees44 Debt/Eq0.03 Sales Y/Y TTM53.80% Profit Margin-32.01% Recom1.00 Target Price6.75
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q32.31% Payout- Rel Volume0.38 Prev Close0.66
Sales Surprise56.62% EPS Surprise45.76% Sales Q/Q20.39% EarningsMay 09 AMC Avg Volume351.17K Price0.66
SMA20-36.28% SMA50-53.27% SMA200-45.64% Trades Volume133,794 Change0.00%
Date Action Analyst Rating Change Price Target Change
Oct-29-21Resumed Stifel Buy $12
Sep-15-21Initiated Cantor Fitzgerald Overweight $14
Jul-14-20Reiterated H.C. Wainwright Buy $14 → $24
Jul-10-20Resumed Stifel Buy $22 → $10
Feb-22-19Initiated SVB Leerink Outperform $16
Jun-12-24 08:00AM
Jun-05-24 08:00AM
Jun-04-24 08:00AM
May-29-24 08:00AM
May-14-24 08:00AM
10:56PM Loading…
May-09-24 10:56PM
May-07-24 08:00AM
Apr-03-24 08:00AM
Apr-01-24 10:15AM
Mar-25-24 09:53PM
08:00AM Loading…
Mar-22-24 08:00AM
Jan-29-24 04:07AM
Dec-21-23 09:52AM
Nov-20-23 11:23AM
Nov-13-23 09:00AM
Nov-08-23 04:01PM
Nov-06-23 08:00AM
Oct-24-23 12:30PM
Oct-19-23 08:00AM
Oct-16-23 08:00AM
Oct-03-23 08:00AM
Oct-02-23 08:00AM
Sep-20-23 08:00AM
Aug-30-23 08:00AM
08:05AM Loading…
Aug-12-23 08:05AM
Aug-09-23 05:30PM
Aug-02-23 04:00PM
Jun-01-23 08:00AM
May-15-23 08:00AM
May-11-23 05:25PM
May-03-23 06:14AM
Apr-24-23 08:00AM
Mar-23-23 04:01PM
Mar-22-23 08:00AM
Feb-17-23 08:00AM
Feb-07-23 08:00AM
Jan-13-23 08:00AM
Dec-23-22 04:01PM
Dec-16-22 08:00AM
Dec-06-22 12:17PM
Nov-14-22 04:01PM
Nov-10-22 08:00AM
Nov-08-22 08:00AM
Nov-03-22 08:00AM
Nov-02-22 08:00AM
Oct-26-22 08:00AM
Sep-27-22 08:15AM
Sep-15-22 08:00AM
Sep-07-22 05:58AM
Sep-06-22 04:00PM
Aug-31-22 08:00AM
Aug-18-22 07:48AM
Aug-15-22 04:01PM
Jul-28-22 08:00AM
Jun-14-22 02:09PM
May-17-22 08:00AM
May-12-22 04:01PM
May-09-22 08:00AM
Apr-25-22 08:00AM
Apr-04-22 08:00AM
Mar-29-22 10:00AM
Mar-28-22 12:00PM
Mar-24-22 08:00AM
Mar-23-22 04:01PM
Mar-04-22 08:00AM
Mar-01-22 08:00AM
Feb-16-22 11:22AM
Feb-15-22 08:00AM
Feb-09-22 08:00AM
Feb-02-22 06:46AM
Jan-10-22 08:00AM
Jan-05-22 08:00AM
Jan-04-22 12:48PM
Dec-13-21 08:00AM
Nov-09-21 08:00AM
Nov-05-21 08:00AM
Nov-04-21 09:00AM
Nov-02-21 11:23AM
Oct-18-21 08:00AM
Sep-30-21 08:00AM
Sep-22-21 08:00AM
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.